Private Advisor Group’s Tarsus Pharmaceuticals TARS Stock Holding History

Private Advisor Group’s Portfolio TARS Stock Details TARS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$1.32M	Buy	+16,828	New	+$1.17M	﹤0.01%	1479

Other funds holding TARS

Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $72.4B AUM 31.32% 1-Year Est. Return

UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $13.5B AUM 16.58% 1-Year Est. Return

TimesSquare Capital Management New York $6.12B AUM 30.01% 1-Year Est. Return

Barclays London, United Kingdom $500B AUM 36.84% 1-Year Est. Return

Allspring Global Investments Charlotte, North Carolina $64.1B AUM 28.9% 1-Year Est. Return

Nuveen Charlotte, North Carolina $420B AUM 34.97% 1-Year Est. Return

Private Advisor Group's TARS Position: Q3 2026 in Review

Private Advisor Group opened a new position in Tarsus Pharmaceuticals (TARS) in Q3 2026: 16,828 shares worth $1.32M. The stake represents ﹤0.01% of the portfolio and ranks #1479 among its holdings.

113 funds tracked by Wall St. Rank hold TARS as of Q3 2026.

Private Advisor Group held 16,828 shares of Tarsus Pharmaceuticals worth $1.32M as of Q3 2026.
Tarsus Pharmaceuticals was a new Private Advisor Group position in Q3 2026.
Tarsus Pharmaceuticals made up ﹤0.01% of Private Advisor Group's portfolio in Q3 2026, its #1479 holding.
113 funds tracked by Wall St. Rank held Tarsus Pharmaceuticals as of Q3 2026.

Based on Private Advisor Group's 13F filing for Q3 2026, filed 10 Nov 2026.